Answers are grounded in this paper and cite their sources.
Rexinoid therapy promotes gene expression and reduces ocular surface disease severity, suggesting potential treatment for dry eyes.
Rexinoid NEt-3IB suppresses inflammatory and stimulates homeostatic gene expression in the monocyte/macrophage lineage and desiccation-induced ocular surface disease. Rexinoid therapy may prove to be a novel approach to treat dry eye by stimulating endogenous production of homeostatic/anti-inflammatory factors.
No takes yet. Share an insight, caveat, or question.
Alam et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: